Combined Bezafibrate and Medroxyprogesterone Acetate: Potential Novel Therapy for Acute Myeloid Leukaemia (original) (raw)
Figure 1
Dose dependent killing by BEZ, MPA and B/M of myeloid cell lines.
Cell viability as % of solvent treated controls was determined in KG1a cells by Cell-Titre Blue assay following 10 days treatment with (A) increasing doses of MPA or BEZ alone, or (B) cross-titrations of BEZ (mM) and MPA (µM). Data shown is mean of N = 3 experiments (C) 5 different myeloid cell lines were treated with either solvent control, 0.5 mM BEZ, 5 µM MPA or the combination (B/M) for 7 days. Cell viability was calculated for treatments relative to solvent treated controls after readings had been adjusted for feeding regimens over the 7 days of treatment. Mean±sem is shown for 5 cell lines from a minimum of N = 3 experiments. Individual datapoints are shown in Figure S1. Statistics * p<0.01.